Radhika Bansal

19PUBLICATIONS
141CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular medicineCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Mar 30, 2026
Management of hematological toxicities after BCMA-directed CAR-T cell therapy.

Joselle Cook, Supriya Gupta, Nadine Abdallah

|Apr 02, 2025
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study.

Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang

|Feb 18, 2025
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Doris K Hansen, Lauren C Peres, Danai Dima

|Oct 04, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Surbhi Sidana, Krina K Patel, Lauren C Peres

|Aug 02, 2024
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil

|Jul 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.

Matthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa

Pageof 4

Frequent Collaborators

11 joint publications

Yi Lin

8 joint publications

Jose Villasboas Bisneto

8 joint publications

Yucai Wang

7 joint publications

Jonas Paludo